Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Composition",
"id" : "239266",
"meta" : {
"versionId" : "24",
"lastUpdated" : "2024-08-26T20:20:31.662Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/m11-report"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 239266</b></p><a name=\"239266\"> </a><a name=\"hc239266\"> </a><a name=\"239266-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 24; Last updated: 2024-08-26 20:20:31+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-m11-report.html\">M11Report</a></p></div><p><b>Artifact Description</b>: </p><div><p>This M11Report Profile of Composition includes the instructions in each section.text.div element for creating an M11Report instance.</p>\n</div><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/239266\">https://fevir.net/resources/Composition/239266</a></p><p><b>identifier</b>: FEvIR Object Identifier/239266</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{http://loinc.org 35528-9}\">CeSHarP Report</span></p><p><b>date</b>: 2024-08-26 20:20:31+0000</p><p><b>author</b>: Brian S. Alper</p><p><b>title</b>: M11 Report Template Instructions</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Label</b></td><td><b>Citation</b></td></tr><tr><td style=\"display: none\">*</td><td>Cite As</td><td>Cite as</td><td><div><p>M11 Report Template Instructions [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 239266. Revised 2024-05-18. Available at: https://fevir.net/resources/Composition/239266. Computable resource at: https://fevir.net/FLI/DocumentForComposition239266.</p>\n</div></td></tr></table></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-description",
"valueMarkdown" : "This M11Report Profile of Composition includes the instructions in each section.text.div element for creating an M11Report instance."
}
],
"url" : "https://fevir.net/resources/Composition/239266",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "239266",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "35528-9",
"display" : "Clinical trial protocol Clinical trial protocol"
}
],
"text" : "CeSHarP Report"
},
"date" : "2024-08-26T20:20:31.662Z",
"author" : [
{
"display" : "Brian S. Alper"
}
],
"title" : "M11 Report Template Instructions",
"custodian" : {
🔗 "reference" : "Organization/118079",
"type" : "Organization",
"display" : "Computable Publishing LLC"
},
"relatesTo" : [
{
"type" : "cite-as",
"label" : "Cite as",
"citation" : "M11 Report Template Instructions [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 239266. Revised 2024-05-18. Available at: https://fevir.net/resources/Composition/239266. Computable resource at: https://fevir.net/FLI/DocumentForComposition239266."
}
],
"section" : [
{
"title" : "Protocol Summary",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section1-protocol-summary"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Protocol Synopsis",
"code" : {
"text" : "section1.1-protocol-synopsis"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Primary and Secondary Objectives and Estimands",
"code" : {
"text" : "section1.1.1-objectives-estimands"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Summarize the primary and secondary objectives and any associated estimands. Consider including a copy of the from Section 3 of the protocol and follow all the same instructions.]</div>"
}
},
{
"title" : "Overall Design",
"code" : {
"text" : "section1.1.2-overall-design"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Key aspects of the trial design include Intervention Model, Control Type, Control Description, Intervention Assignment Method, Population Type, Population Diagnosis or Condition (use SNOMED or MedDRA), Population Age (Minimum, Maximum), and Site Distribution and Geographic Scope. Entries should Reference Composition Resource or ResearchStudy Resource.]</div>"
}
},
{
"title" : "Number of Arms",
"code" : {
"text" : "Number of Arms"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter the numeric value for the number of arms in the trial. For trials with a different number of arms in different periods, populate this field based on the total number of arms.]</div>"
}
},
{
"title" : "Blinding",
"code" : {
"text" : "Blinding"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[For designs in which these details may differ in one or more trial periods, answer according to the portion of the trial in which the highest number of blinded roles occurs. More details can be provided in Section 6.6 of the protocol. State 'Blinded roles: The following roles indictated will not be made aweare of the treatment group assignment during the trial:' [blinded roles] 'Not applicable (No blinding)' indicates an open-label trial.]</div>"
}
},
{
"title" : "Number of Participants",
"code" : {
"text" : "Number of Participants"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[State the expected number of participants to be assigned to trial intervention/enrolled. Indicate whether the number provided is the target or maximum number of individuals to be randomly assigned to trial intervention/enrolled.]</div>"
}
},
{
"title" : "Duration",
"code" : {
"text" : "Duration"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[See Template instructions. Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (for example, “event-driven” or “adaptive design”.]</div>"
}
},
{
"title" : "Committees",
"code" : {
"text" : "Committees"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Indicate whether any committee(s) will be reviewing data while the trial is ongoing, and the type of committee. Common examples include Data Monitoring Committee, Dose Escalation Committee, or Endpoint Adjudication Committee; describe others, if applicable. List independent committees in the space indicated. Other committees may be included at the Sponsor’s discretion in the separate space provided. Committees listed here should be fully described in Section 11.3.]</div>"
}
}
]
},
{
"title" : "Trial Schema",
"code" : {
"text" : "section1.2-trial-schema"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[The purpose of this section is to provide a visual depiction of the trial design, orienting users of the protocol to the key features of the design. The schema depicts the trial arms, the flow of individual participants through the progression of trial period(s)/epochs (such as screening, washout/run-in, intervention, and key milestones [for example, randomisation, cross-over, end of treatment]). For complex trials, additional schemas may be added to describe activities or trial periods in greater detail. Entries should Reference SoaPlanDefinition Profile of PlanDefinition Resource.]</div>"
}
},
{
"title" : "Schedule of Activities",
"code" : {
"text" : "section1.3-schedule-of-activities"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[The schedule of activities must capture the procedures that will be accomplished at each trial visit, and all contact with participants, for example, telephone contacts. This includes any tests that are used for eligibility, participant randomisation or stratification, or decisions on trial intervention discontinuation. Allowable windows should be stated for all visits and procedures. A tabular format is recommended. Entries should Reference SoaPlanDefinition Profile of PlanDefinition Resource.]</div>"
}
}
]
},
{
"title" : "Introduction",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section2-introduction"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Purpose of Trial",
"code" : {
"text" : "section2.1-trial-purpose"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Explain why the trial is needed, why the research questions being asked are important. Do not restate the IB.]</div>"
}
},
{
"title" : "Summary of Benefits and Risks",
"code" : {
"text" : "section2.2-benefits-risks"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include an assessment of known and potential risks and benefits, if any, from the perspective of an individual participant, including the basis of the risk (for example, nonclinical studies or prior clinical trials). Optional level 3 subheadings are provided to assist with organization of the section; alternatively, the section may be summarized in a single section utilizing the overall benefit-risk entry point.]</div>"
},
"section" : [
{
"title" : "Benefit Summary",
"code" : {
"text" : "section2.2.1-benefit-summary"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[The benefit summary should be written from the perspective of an individual participant, and should describe any physical, psychological, social, legal, or any other potential benefits to individual participants as a result of participating in the trial, addressing immediate potential benefits and/or long-range potential benefits. Clearly state if no benefits to an individual participant can be anticipated, or if potential benefits are unknown. For early clinical trials such as Phase 1, benefits for an individual participant (other than those of altruism) are expected to be minimal. Benefits to society in general may also be included but should be described separately.]</div>"
}
},
{
"title" : "Risk Summary and Mitigation Strategy",
"code" : {
"text" : "section2.2.2-risk-summary"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[You may enter the entire risk summary here or use the subsections for Trial Intervention, Trial Procedures, and Other as noted below.]</div>"
},
"section" : [
{
"title" : "Trial-specific Intervention Risks and Mitigations",
"code" : {
"text" : "section2.2.2.1-trial-intervention-risk-summary"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Trial Intervention – Describe risks related to trial-specific treatments and interventions. For the protocol, focus only on the relevant key risks for THIS trial. Provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section. Include an assessment of known benefits and potential risks, including the basis of the risk (for example, preclinical studies or prior clinical trials).]</div>"
}
},
{
"title" : "Trial-specific Procedure Risks and Mitigations",
"code" : {
"text" : "section2.2.2.2-trial-procedures-risk-summary"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Trial Procedures – Consider risks associated with the design (for example, placebo arm) and procedures specific to THIS trial (for example, biopsies), and any measures to control the risks. Provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section. This is not intended to be an exhaustive list of all possible risks associated with trial procedures but should focus on the unique risks inherent in the design or less common or high-risk procedures. As above, provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section.]</div>"
}
},
{
"title" : "Trial-specific Other Risks and Mitigations",
"code" : {
"text" : "section2.2.2.3-trial-other-risk-summary"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Other – Consider risks associated with other items (for example, comparators, challenge agents, imaging agents, medical devices). Insert a line for each, as needed.]</div>"
}
}
]
},
{
"title" : "Overall Benefit:Risk Conclusion",
"code" : {
"text" : "section2.2.3-overall-benefit-risk-conclusion"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Provide a succinct, concluding statement on the perceived balance between risks that have been identified from cumulative safety data, protocol procedures, and anticipated efficacy/benefits within the context of the proposed trial. Risks need to be assessed against the benefits for the individual participant at least once a year.]</div>"
}
}
]
}
]
},
{
"title" : "Trial Objectives and Estimands",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section3-estimands"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Primary Objective(s) and Associated Estimand(s)",
"code" : {
"text" : "section3.1-primary-objective-estimand"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[For all trials, precisely state each primary and secondary trial objective by providing a meaningful and concise description of the treatment effect of interest using natural, non-technical language for clear understanding of sponsors, investigators, clinical site personnel, trial participants, ethics committees, and regulators.]</div>"
},
"section" : [
{
"title" : "Primary Objective",
"code" : {
"text" : "section3.1-objective-endpoint-estimand"
},
"focus" : {
"type" : "EvidenceVariable",
"display" : "[Replace with VariableDefinition Profile of EvidenceVariable Resource.]"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[For trials intended to estimate a treatment effect or test a hypothesis related to a treatment effect, use the table to precisely describe the associated estimand(s). This includes specification of the target population, the treatment condition(s), the endpoint (or variable), the population-level summary, and each intercurrent event and the associated strategy for handling it. For other types of trials not intended to estimate a treatment effect or test a hypothesis related to a treatment effect, describe additional information relevant to the clinical question(s) of interest (e.g., the endpoint(s) associated with each objective).]</div>"
},
"section" : [
{
"title" : "Population",
"code" : {
"text" : "estimand-population"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[List of key characteristics, such as demographic characteristics (e.g., age, sex) and clinical characteristics (e.g., prior therapies, symptoms, severity, biomarker status)]</div>"
}
},
{
"title" : "Treatment",
"code" : {
"text" : "estimand-treatment"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[List of key aspects of treatment regimens in each study group, including at least investigational agents, dosage, and administration route]</div>"
}
},
{
"title" : "Endpoint",
"code" : {
"text" : "Endpoint"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Definition of the endpoint]</div>"
}
},
{
"title" : "Population-Level Summary",
"code" : {
"text" : "statistic-type"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Description of the population-level summary (e.g., mean difference, relative risk)]</div>"
}
},
{
"title" : "Intercurrent Event",
"code" : {
"text" : "intercurrent-event"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[This may later be replaced with a repeatable section. For each intercurrent event, provide (1) Description of Intercurrent Event 1 (e.g., permanent discontinuation of trial intervention) and (2) Description of the strategy to address the intercurrent event (e.g., a treatment policy strategy); cross-reference the justification in Section 4]</div>"
}
}
]
}
]
},
{
"title" : "Secondary Objective(s) and Associated Estimand(s)",
"code" : {
"text" : "section3.2-secondary-objective-estimand"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the secondary objective(s) and associated estimand(s) as outlined in Section 3.1. Use the same approach as above and consider including a table for a precise estimand description.]</div>"
},
"section" : [
{
"title" : "Secondary Objective",
"code" : {
"text" : "section3.2-objective-endpoint-estimand"
},
"focus" : {
"type" : "EvidenceVariable",
"display" : "[Replace with VariableDefinition Profile of EvidenceVariable Resource.]"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Population",
"code" : {
"text" : "estimand-population"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[List of key characteristics, such as demographic characteristics (e.g., age, sex) and clinical characteristics (e.g., prior therapies, symptoms, severity, biomarker status)]</div>"
}
},
{
"title" : "Treatment",
"code" : {
"text" : "estimand-treatment"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[List of key aspects of treatment regimens in each study group, including at least investigational agents, dosage, and administration route]</div>"
}
},
{
"title" : "Endpoint",
"code" : {
"text" : "Endpoint"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Definition of the endpoint]</div>"
}
},
{
"title" : "Population-Level Summary",
"code" : {
"text" : "statistic-type"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Description of the population-level summary (e.g., mean difference, relative risk)]</div>"
}
},
{
"title" : "Intercurrent Event",
"code" : {
"text" : "intercurrent-event"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[This may later be replaced with a repeatable section. For each intercurrent event, provide (1) Description of Intercurrent Event 1 (e.g., permanent discontinuation of trial intervention) and (2) Description of the strategy to address the intercurrent event (e.g., a treatment policy strategy); cross-reference the justification in Section 4]</div>"
}
}
]
}
]
},
{
"title" : "Exploratory Objective(s)",
"code" : {
"text" : "section3.3-exploratory-objective-estimand"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[State each exploratory objective. This should generally include documentation of associated exploratory endpoints. It may be helpful in some cases to describe precise estimands to provide clarity on what is being estimated.]</div>"
},
"section" : [
{
"title" : "Exploratory Objective",
"code" : {
"text" : "section3.3-objective-endpoint-estimand"
},
"focus" : {
"type" : "EvidenceVariable",
"display" : "[Replace with VariableDefinition Profile of EvidenceVariable Resource.]"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Population",
"code" : {
"text" : "estimand-population"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[List of key characteristics, such as demographic characteristics (e.g., age, sex) and clinical characteristics (e.g., prior therapies, symptoms, severity, biomarker status)]</div>"
}
},
{
"title" : "Treatment",
"code" : {
"text" : "estimand-treatment"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[List of key aspects of treatment regimens in each study group, including at least investigational agents, dosage, and administration route]</div>"
}
},
{
"title" : "Endpoint",
"code" : {
"text" : "Endpoint"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Definition of the endpoint]</div>"
}
},
{
"title" : "Population-Level Summary",
"code" : {
"text" : "statistic-type"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Description of the population-level summary (e.g., mean difference, relative risk)]</div>"
}
},
{
"title" : "Intercurrent Event",
"code" : {
"text" : "intercurrent-event"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[This may later be replaced with a repeatable section. For each intercurrent event, provide (1) Description of Intercurrent Event 1 (e.g., permanent discontinuation of trial intervention) and (2) Description of the strategy to address the intercurrent event (e.g., a treatment policy strategy); cross-reference the justification in Section 4]</div>"
}
}
]
}
]
}
]
},
{
"title" : "Trial Design",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section4-trial-design"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Description of Trial Design",
"code" : {
"text" : "section4.1-description-of-trial-design"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the trial intervention model (for example, single group, parallel group, cross-over, factorial, sequential), the expected number of participants, and the control method (for example, placebo, active comparator, low dose, historical, standard of care, sham procedure, or none [uncontrolled]). If applicable, indicate other design characteristics (for example, superiority, non-inferiority, dose escalation, or equivalence). If the trial will have an adaptive or novel design (for example, the trial will be conducted under a master protocol), provide a summary of these design aspects. Describe the trial duration with reference to Section 1.2, Trial Schema. Explain what the overall duration for an individual participant is anticipated to be and why, including the sequence and duration of trial periods (for example, screening, run-in, randomisation, treatment [fixed dose/titration], follow-up/washout periods). Where applicable, include discussion of sentinel dosing (or lack thereof), dose escalation, and cohort expansion. If dose modification decisions are dependent upon review by a committee, include details in Section 11.3, Committees. Describe the method of assignment to trial intervention (for example, stratified randomisation) with reference to Section 6.6. If assignment to trial intervention is by randomisation, describe when randomisation occurs relative to screening. Describe the level and method of blinding with reference to Section 6.6 (for example, single-blind, double-blind, [including sponsor unblinded], matching placebo, double-dummy, or open-label). Include mention of measures taken to minimise bias on the part of participants, investigators, and analysts. If applicable, describe within-trial transition rules, for example, transitions involving cohorts or trial parts. Dose escalation or dose-ranging details should also be described. Discuss any other important aspects of the design, including but not limited to the following, where applicable: •\tGeographic scope of trial (for example, single-centre, multi-centre, or multi-centre and multi-national) • Use of decentralised processes, tools, or features in the trial •\tPlanned use of a Data Monitoring Committee, or similar review group and cross-reference Section 11.3, Committees, for details, •\tWhether an interim analysis is planned and, if so, refer to details in Section 10.7, Interim Analysis, and/or • Any planned extension trial, long-term follow-up/registry, planned future use of samples or data, or post-trial sample analysis or other data-related activities.]</div>"
},
"section" : [
{
"title" : "Stakeholder Input into Design",
"code" : {
"text" : "section4.1.1-stakeholder-input-into-design"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any stakeholder (for example, patient, healthcare professional and patient advocacy groups) involvement in the design of the trial and any suggestions implemented.]</div>"
}
}
]
},
{
"title" : "Rationale for Trial Design",
"code" : {
"text" : "section4.2-rationale-for-trial-design"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Rationale for Intervention Model",
"code" : {
"text" : "section4.2.1-rationale-intervention-model"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Provide a rationale for the trial intervention model selected in Section 4.1, Description of Trial Design with a cross-reference to Section 6.2, Rationale for Investigational Intervention(s). Rationale for choice of comparator, if applicable, should be described separately in Section 4.2.5, Rationale for Comparator. A rationale for the choice of trial population should be described separately in Section 5.1, Description of Trial Population and Rationale.]</div>"
}
},
{
"title" : "Rationale for Duration",
"code" : {
"text" : "section4.2.2-rationale-duration"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Provide a rationale that the trial duration is appropriate for a reliable and relevant evaluation of the trial intervention per the trial objective(s).]</div>"
}
},
{
"title" : "Rationale for Estimands",
"code" : {
"text" : "section4.2.3-rationale-estimands"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Provide a rationale for the trial estimand(s) described in Section 3. This should include a rationale that the selected endpoint(s) are clinically relevant and provide a reliable and valid measurement of the intended intervention effect. It should also include a rationale for the selected strategies for handling intercurrent events.]</div>"
}
},
{
"title" : "Rationale for Interim Analysis",
"code" : {
"text" : "section4.2.4-rationale-interim-analysis"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, provide a rationale for any interim analysis planned with respect to its purpose (for example, stopping the trial early for efficacy or futility) and timing.]</div>"
}
},
{
"title" : "Rationale for Control Type",
"code" : {
"text" : "section4.2.5-rationale-comparator"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, provide a rationale for the type and choice of control selected for the trial (for example, placebo, active drug, combination, historical). Describe any known or potential problems associated with the control group selected in light of the specific disease and intervention(s) being studied. If comparators will differ by region, describe.]</div>"
}
},
{
"title" : "Rationale for Adaptive or Novel Trial Design",
"code" : {
"text" : "section4.2.6-rationale-adaptive"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, provide a rationale for the use of an adaptive or novel design.]</div>"
}
},
{
"title" : "Rationale for Other Trial Design Aspects",
"code" : {
"text" : "section4.2.7-rationale-other-aspects"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Discuss rationale for any additional aspects of the design not addressed above.]</div>"
}
}
]
},
{
"title" : "Trial Stopping Rules",
"code" : {
"text" : "section4.3-trial-stopping-rules"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any trial-specific stopping rules, including guidance on when the trial should be stopped for safety reasons, when a cohort or dose escalation should be terminated, and/or when a given treatment arm should be terminated. If applicable, describe any rules that may result in a temporary pause of dosing and/or enrollment into the trial and criteria for restarting enrollment. Ensure that the trials stopping rules are aligned with the specifications that are described in Section 10.9 for Interim Analyses.]</div>"
}
},
{
"title" : "Start of Trial and End of Trial",
"code" : {
"text" : "section4.4-start-and-end"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Define key timepoints in the trial, including trial start and end dates. For example, a key timepoint definition for start of trial might be when the informed consent is signed by the first participant and a key timepoint definition for end of trial might be when participants are no longer being examined or the last participant’s last study assessment has occurred. If applicable, consider local regulatory requirements for these and other definitions (for example, the first act of recruitment). If appropriate, provide a cross-reference to Section 11.6]</div>"
}
},
{
"title" : "Access to Trial Intervention After End of Trial",
"code" : {
"text" : "section4.5-access-after-trial"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any possibilities for access to trial intervention, if any, beyond completion of the trial. Planned extension trials, if described above in Section 4.1 do not need to be repeated.]</div>"
}
}
]
},
{
"title" : "Trial Population",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section5-trial-population"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Description of Trial Population and Rationale",
"code" : {
"text" : "section5.1-population-description"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the population selected (for example, healthy participants, adult participants, paediatric participants) and how the enrollment criteria reflect the populations that are likely to use the drug if approved. Specify the population age range (for example, ≤3 months, ≥18 to ≤80 years old) including the time point at which qualification for age criteria is determined (for example, at time of screening vs randomization for paediatric trials). Specify any key diagnostic criteria for the population (for example, “acute lung injury”, or a specific biomarker profile). If applicable, describe similar conditions or diseases and their differential diagnosis. Provide a rationale for the trial population ensuring that the population selected is well defined and clinically recognisable. Describe how the selected population can meet the trial objectives and how the enrollment criteria reflects the targeted populations. Justify whether the trial intervention is to be evaluated in paediatric participants, in adults unable to consent for themselves, other vulnerable participant populations, or those that may respond to the trial intervention differently (for example, elderly, hepatic or renally impaired, or immunocompromised participants). Entries should Reference CohortDefinition (or StudyEligibilityCriteria) Profile of Group Resource.]</div>"
}
},
{
"title" : "Inclusion Criteria",
"code" : {
"text" : "section5.2-inclusion-criteria"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Inclusion criteria are characteristics that define the trial population, for example, those criteria that every potential participant must satisfy, to qualify for trial entry. Add criteria as needed. Number sequentially. Entries should Reference CohortDefinition (or StudyEligibilityCriteria) Profile of Group Resource.]</div>"
}
},
{
"title" : "Exclusion Criteria",
"code" : {
"text" : "section5.3-exclusion-criteria"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Exclusion criteria are characteristics that make an individual ineligible for participation. Add criteria as needed. Number the criteria sequentially. Entries should Reference CohortDefinition (or StudyEligibilityCriteria) Profile of Group Resource.]</div>"
}
},
{
"title" : "Contraception",
"code" : {
"text" : "section5.4-contraception"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Definitions Related to Childbearing Potential",
"code" : {
"text" : "section5.4.1-contraception-definitions"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the definitions of • Participant of childbearing potential, and • Participant of non-childbearing potential]</div>"
}
},
{
"title" : "Contraception Requirements",
"code" : {
"text" : "section5.4.2-contraception-details"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the: • Contraceptive methods required, and • Duration of use]</div>"
}
}
]
},
{
"title" : "Lifestyle Restrictions",
"code" : {
"text" : "section5.5-lifestyle-restrictions"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[In the following subsections, describe any restrictions during the trial pertaining to lifestyle and/or diet, intake of caffeine, alcohol, or tobacco, or physical and other activities. If not applicable, include a statement that no restrictions are required.]</div>"
},
"section" : [
{
"title" : "Meals and Dietary Restrictions",
"code" : {
"text" : "section5.5.1-dietary-restrictions"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any restrictions on diet (for example, food and drink restrictions, timing of meals relative to dosing).]</div>"
}
},
{
"title" : "Caffeine, Alcohol, Tobacco, and Other Restrictions",
"code" : {
"text" : "section5.5.2-substances-restrictions"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any restrictions on the intake of caffeine, alcohol, tobacco, or other restrictions.]</div>"
}
},
{
"title" : "Physical Activity Restrictions",
"code" : {
"text" : "section5.5.3-activity-restrictions"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any restrictions on activity (for example, in first-in-human trials, activity may be restricted by ensuring participants remain in bed for 4 to 6 hours after dosing).]</div>"
}
},
{
"title" : "Other Activity Restrictions",
"code" : {
"text" : "section5.5.4-other-restrictions"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe restrictions on any other activity (for example, blood or tissue donation); or any other activity restrictions, such as on driving, heavy machinery use, or sun exposure.]</div>"
}
}
]
},
{
"title" : "Screen Failure and Rescreening",
"code" : {
"text" : "section5.6-screen-failure"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Indicate how screen failure will be handled in the trial, including conditions and criteria upon which rescreening is acceptable. If applicable, indicate the circumstances and time window under which a repeat procedure is allowed for screen failure relating to specific inclusion/exclusion criteria for the trial.]</div>"
}
}
]
},
{
"title" : "Trial Intervention and Concomitant Therapy",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section6-trial-intervention"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Overview of Trial Interventions",
"code" : {
"text" : "section6.1-overview-of-trial-interventions"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter a Table of Trial Interventions. See Template Instructions for details.]</div>"
}
},
{
"title" : "Description of Investigational Trial Intervention",
"code" : {
"text" : "section6.2-description-of-trial-intervention"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[The investigational trial intervention(s) should be described concisely in a table. Describe the investigational trial intervention to be administered in each arm of the trial and for each period of the trial including route and mode of administration, dose, dosage regimen, duration of intervention, use, packaging and labelling. Refer to approved regional labelling, as appropriate. For drug/device combination products, include details on the configuration and use of the device and device manufacturer. A device user manual may be referenced in this section. Entries should Reference ExposureDefinition Profile of Group Resource.]</div>"
}
},
{
"title" : "Rationale for Investigational Trial Intervention Dose and Regimen",
"code" : {
"text" : "section6.3-rationale-for-trial-intervention-regimen"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Provide a rationale for the selection of the dose(s) or dose range, the route of administration, and dosing regimen of the investigational trial intervention. This rationale should include relevant results from previous preclinical studies and clinical trials that support selection of the dose and regimen. Discuss impact of differences in study population characteristics (for example, age, sex and/or race) which could lead to differences in pharmacokinetics and pharmacodynamics in this study as compared to previous studies. If applicable, justify any differences in dose regimen or therapeutic use relative to approved labelling. Describe prior trials and other information that support the dose and/or dose regimen of the investigational intervention. Include a rationale for prospective dose adjustments incorporated in the trial, if any. Entries should Reference ExposureDefinition Profile of Group Resource.]</div>"
}
},
{
"title" : "Investigational Trial Intervention Administration",
"code" : {
"text" : "section6.4-dosing-and-administration"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the detailed procedures for administration of each participant’s dose of investigational trial intervention. This may include the timing of dosing (for example, time of day, interval), the duration (for example, the length of time participants will be administered the investigational trial intervention), the planned route of administration (for example, oral, nasal, intramuscular), and the timing of dosing relative to meals. Include any specific instructions to trial participants about when or how to prepare and take the dose(s) and how delayed or missed doses should be handled. Dose escalation or cohort expansion as part of the overall design should be covered in Section 4.1 (Description of Trial Design). Entries should Reference ActivityDefinition Resource.]</div>"
}
},
{
"title" : "Investigational Trial Intervention Dose Modification",
"code" : {
"text" : "section6.5-dose-modification"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[For each participant, describe any dose modifications allowed, including conditions for such dose modifications, particularly regarding failure to respond or safety concerns. State any minimum period required before a participant’s dose might be raised to the next higher dose or dose range. Include whether it is permissible to start and stop treatment and how dose reductions (if permitted) are to be managed. Information on stopping investigational trial intervention for an individua participant due to safety/other reasons should be detailed in Section 7, Participant Discontinuation of Trial Intervention and Withdrawal from Trial. Entries should Reference ActivityDefinition Resource.]</div>"
}
},
{
"title" : "Management of Investigational Trial Intervention Overdose",
"code" : {
"text" : "section6.6-management-of-overdose"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe what is meant by investigational trial intervention overdose. Provide any available information on managing the overdose and ensure it is consistent with the Investigator’s Brochure or product labelling, cross-references these documents as applicable. Entries should Reference ActivityDefinition Resource or PlanDefinition Resource.]</div>"
}
},
{
"title" : "Preparation, Storage, Handling and Accountability of Investigational Trial Intervention(s)",
"code" : {
"text" : "section6.7-preparation-storage-handling"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Preparation of Investigational Trial Intervention(s)",
"code" : {
"text" : "section6.7.1-preparation"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe any preparation of the investigational trial intervention, and when necessary, by whom. When applicable, describe the maximum hold time once thawed/mixed before administration. Include thawing, diluting, mixing, and reconstitution/preparation instructions in this section. For drug/device combination products, include any relevant assembly or use instructions and reference the package insert that is provided separately. If the instructions are lengthy or complicated, it is acceptable to reference the package insert (if applicable) or include instructions in a separate document(s) provided to the site (for example, a pharmacy manual). If the latter, reference the separate documents.]</div>"
}
},
{
"title" : "Storage and Handling of Investigational Trial Intervention",
"code" : {
"text" : "section6.7.2-storage-handling"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe storage and handling requirements (for example, protection from light, temperature, humidity) for the investigational trial intervention(s). For trials in which multi-dose vials are utilised, provide additional information regarding stability and expiration time after initial use (for example, the seal is broken). State how the investigational trial intervention(s) will be provided to the Investigator. If applicable, describe the kits, packaging, or other material of the investigational trial intervention for blinding purposes. If the instructions are lengthy or complicated, it is acceptable to reference the package insert (if applicable) or include instructions in a separate document(s) provided to the site (for example, a pharmacy manual). If the latter, reference the separate documents.]</div>"
}
},
{
"title" : "Accountability of Investigational Trial Intervention",
"code" : {
"text" : "section6.7.3-accountability"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the accountability method, including how the investigational trial intervention will be distributed and related details, including: •\thow and by whom the investigational trial intervention will be distributed • participation of a drug storage repository or pharmacy, if applicable, •\tplans for disposal or return of unused product, •\tif applicable, plans for reconciliation of investigational trial intervention.]</div>"
}
}
]
},
{
"title" : "Investigational Trial Intervention Assignment, Randomisation and Blinding",
"code" : {
"text" : "section6.8-assignment-randomisation-blinding"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Participant Assignment to Investigational Trial Intervention",
"code" : {
"text" : "section6.8.1-assignment"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the method of assigning participants to investigational trial intervention without being so specific that blinding or randomisation might be compromised. If assignment to investigational trial intervention is by randomisation, describe when randomisation occurs relative to screening. State that at enrollment, participant identification codes should be assigned. If adaptive randomisation or other methods of covariate balancing/minimisation are employed, include a cross-reference to the methods of analysis in Section 10, Statistical Considerations. As applicable, details regarding the implementation of procedures to minimise bias should be described.]</div>"
}
},
{
"title" : "Randomisation",
"code" : {
"text" : "section6.8.2-randomisation"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the randomisation procedures (for example, central randomisation procedures), the method used to generate the randomisation schedule (for example, computer generated), the source of the randomisation schedule (for example, sponsor, investigator, or other), and whether or not IxRS will be used. To maintain the integrity of the blinding, do not include the block size. Describe the use and validation of any computer systems and programmes used for randomisation.]</div>"
}
},
{
"title" : "Blinding",
"code" : {
"text" : "section6.8.3-blinding"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe efforts to ensure that the investigational trial intervention(s) are as indistinguishable as possible. Plans for the maintenance of randomisation codes and appropriate blinding for the trial should be described. Procedures for planned and unplanned (for example, safety events) breaking of randomisation codes should be provided. If the trial allows for some investigators or other designated staff to remain unblinded (for example, to allow them to adjust investigational trial intervention), the means of maintaining the blinding for other investigators or staff should be explained. Measures to prevent unblinding by laboratory measurements or while performing study assessments, if used, should be described.]</div>"
}
},
{
"title" : "Emergency Unblinding at the Site",
"code" : {
"text" : "section6.8.4-unblinding"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the criteria for breaking the trial blind or participant code. Describe the circumstances in which the blinding would be broken for an individual or for all participants and who has responsibility. Include the procedure for emergency unblinding such as via IxRS or code envelopes as well as documentation of unblinding. Indicate to whom the intentional and unintentional unblinding should be reported.]</div>"
}
}
]
},
{
"title" : "Investigational Trial Intervention Compliance",
"code" : {
"text" : "section6.9-intervention-compliance"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe measures employed to ensure and document dosing information and investigational trial intervention compliance (for example, accountability records, diary cards, or concentration measurements). Include a description of what documents are mandatory to complete (for example, participant drug log) and what source data/records will be used to document investigational trial intervention compliance.]</div>"
}
},
{
"title" : "Non-Investigational Trial Intervention(s)",
"code" : {
"text" : "section6.10-noninvestigational-interventions"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[As stated in Section 6, non-investigational interventions are products used in the trial but are not part of trial objectives and hence, are not investigational trial interventions. The non-investigational trial intervention(s) may be described concisely in a table or in the following sections as applicable.]</div>"
},
"section" : [
{
"title" : "Background Intervention",
"code" : {
"text" : "section6.10.1-background-intervention"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe background interventions, including administration and any conditions for use.]</div>"
}
},
{
"title" : "Rescue Therapy",
"code" : {
"text" : "section6.10.2-rescue-therapy"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[List all rescue medications, treatments, and/or procedures, including any relevant instructions about their administration and any conditions for their use. If administration of rescue therapy leads to the temporary discontinuation of trial intervention or a participant’s withdrawal from the trial, refer to Section 7, Participant Discontinuation of Trial Intervention and Withdrawal from Trial.]</div>"
}
},
{
"title" : "Other Therapy",
"code" : {
"text" : "section6.10.3-other-therapy"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe the use of other non-investigational or auxiliary therapy, for example, challenge agents or diagnostics.]</div>"
}
}
]
},
{
"title" : "Concomitant Therapy",
"code" : {
"text" : "section6.11-concomitant-therapy"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the concomitant medications, supplements, complementary and alternative therapies, treatments, and/or procedures which are allowed or prohibited during the trial, and include details about when the information will be collected (for example, screening, all visits). This section should be consistent with the medication restrictions in the inclusion/exclusion criteria previously listed.]</div>"
},
"section" : [
{
"title" : "Prohibited Concomitant Therapy",
"code" : {
"text" : "section6.11.1-prohibited-concomitant-therapy"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any prohibited concomitant therapy.]</div>"
}
},
{
"title" : "Permitted Concomitant Therapy",
"code" : {
"text" : "section6.11.2-permitted-concomitant-therapy"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any permitted concomitant therapy.]</div>"
}
}
]
}
]
},
{
"title" : "Participant Discontinuation of Trial Intervention and Discontinuation or Withdrawal from Trial",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section7-participant-discontinuation"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Discontinuation of Trial Intervention for Individual Participants",
"code" : {
"text" : "section7.1-discontinuation-of-trial-intervention"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Permanent Discontinuation of Trial Intervention",
"code" : {
"text" : "section7.1.1-permanent-discontinuation-of-trial-intervention"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the criteria for discontinuation of a participant from any trial intervention, carefully evaluating which are appropriate for the trial population and therapy being studied. Specify whether participants who discontinue trial intervention can or cannot continue the trial (continue trial visits). Refer to the Section 1.3 Schedule of Activities for assessments to be performed at the time of and following discontinuation of trial intervention. Explain the process for collecting and recording the detailed reasons for discontinuing trial intervention(s).]</div>"
}
},
{
"title" : "Temporary Discontinuation of Trial Intervention",
"code" : {
"text" : "section7.1.2-temporary-discontinuation-of-trial-intervention"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe •\tthe criteria for temporary discontinuation or interruption of trial intervention for an individual participant •\twhat to do and which restrictions still apply if the participant needs to temporarily discontinue or interrupt trial intervention •\twhether they will continue in the trial, and •\twhether all, or specify which, assessments will be performed for the stated duration of the trial. Details of any rechallenge or restart after a safety-related event should be included in Section 7.1.3, Rechallenge.]</div>"
}
},
{
"title" : "Rechallenge",
"code" : {
"text" : "section7.1.3-rechallenge"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the criteria for rechallenge/restarting trial intervention, how to perform rechallenge, number of rechallenges allowed during the trial, and whether all, or specify which, assessments will be performed for the stated duration of the trial. If rechallenge is not allowed, state this.]</div>"
}
}
]
},
{
"title" : "Discontinuation or Withdrawal from the Trial",
"code" : {
"text" : "section7.2-participant-withdrawal"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the criteria for participant withdrawal from the trial. Describe the reason for withdrawal and the type and data to be collected for the final assessments with reference to the schedule of activities for the participant end of study visit unless provided in another section.]</div>"
}
},
{
"title" : "Lost to Follow-Up",
"code" : {
"text" : "section7.3-lost-to-follow-up"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe how the trial will define loss to follow-up. In general, participants should be considered lost to follow-up only if they cannot be reached despite multiple attempts at contact. Describe how reasons for loss to follow-up (when available) will be documented. Also describe approaches that will be used to minimize loss to follow-up, such as multiple, diverse methods to remain in contact with participants (e.g., telephone calls, texts, and emails to the participant).]</div>"
}
}
]
},
{
"title" : "Trial Assessments and Procedures",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section8-assessments"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Trial Assessments and Procedures Considerations",
"code" : {
"text" : "section8.1-assessments-procedures"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter general trial assessments and procedures text, if needed.]</div>"
}
},
{
"title" : "Screening/Baseline Assessments and Procedures",
"code" : {
"text" : "section8.2-screening-baseline-assessments"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe any assessments and procedures that are unique to screening/baseline (for example, collection of data on participant characteristics, assessments/procedures performed for the purpose of determining eligibility or for stratification) in this section. Describe screening and baseline assessments and procedures separately if screening and baseline are performed at different visits.]</div>"
}
},
{
"title" : "Efficacy Assessments and Procedures",
"code" : {
"text" : "section8.3-efficacy-assessments"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe efficacy assessments and procedures in this section. Cross-refer to Section 8.7 if immunogenicity assessments are used in efficacy determination.]</div>"
}
},
{
"title" : "Safety Assessments and Procedures",
"code" : {
"text" : "section8.4-safety-assessments"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Physical Examination",
"code" : {
"text" : "section8.4.1-physical-examination"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include any specific instructions for the collection and interpretation of physical examinations.]</div>"
}
},
{
"title" : "Vital Signs",
"code" : {
"text" : "section8.4.2-vital-signs"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include any specific instructions for the collection and interpretation of vital signs.]</div>"
}
},
{
"title" : "Electrocardiograms",
"code" : {
"text" : "section8.4.3-electrocardiograms"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include any specific instructions for the collection, interpretation, and archiving of ECGs.]</div>"
}
},
{
"title" : "Clinical Laboratory Assessments",
"code" : {
"text" : "section8.4.4-clinical-laboratory-assessments"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include any specific instructions for the collection and interpretation of clinical laboratory assessments. •\tType of laboratory (central/local/hybrid) •\tacceptability of additional tests deemed necessary by the investigator or local regulations •\tinstructions for situations in which central laboratory results are not available in time for trial intervention and/or response evaluation, or in the event of a severe disruption (for example, a pandemic or natural disaster) •\ttreatment algorithms for results out of normal range •\tCross-refer to Section 13.2 for lab assessment panels]</div>"
}
},
{
"title" : "Pregnancy Testing",
"code" : {
"text" : "section8.4.5-pregnancy-testing"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Optional section to specify pregnancy testing requirements.]</div>"
}
},
{
"title" : "Suicidal Ideation and Behaviour Risk Monitoring",
"code" : {
"text" : "section8.4.6-suicidal-ideation"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If the trial meets any of the criteria requiring suicidal ideation and behaviour risk monitoring by the guidance/guideline in each region, include justification for the need for suicidal ideation and behaviour risk monitoring in the study and add any specific instructions for the collection and interpretation of the assessment. In case this is an AESI in the study, justification will also need to be provided in the appropriate subsection of Section 9.4.]</div>"
}
}
]
},
{
"title" : "Pharmacokinetics",
"code" : {
"text" : "section8.5-pharmacokinetics"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include any specific instructions for the collection and assay of samples and interpretation of PK assessments. If pharmacokinetic testing is not included in the study, state “Not Applicable.” •\tDescribe the biological sample(s) collected, the handling of samples, and the assay method. o\tSpecific sample collection and processing instructions can be described in an appendix or a separate document and cross-referenced. •\tDescribe the retention time for the samples (ensuring alignment with the ICF). •\tIndicate the types of analyses that may be studied for each sample.]</div>"
}
},
{
"title" : "Biomarkers",
"code" : {
"text" : "section8.6-biomarkers"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only). Include any specific instructions for the collection of samples and assessment of biomarkers, including pharmacodynamics. If biomarker or pharmacodynamic testing is not included in the study, state “Not Applicable.” •\tDescribe the biological samples that will be collected (for example, tissue, serum, plasma, etc.). o\tSpecific sample collection and processing instructions can be described in an appendix or a separate document and cross-referenced. •\tDescribe the retention time for the samples (ensuring alignment with the ICF). •\tIndicate the types of biomarkers that will be studied for each sample. •\tSpecify whether each sample is optional or required. Required samples must be based on a protocol objective.]</div>"
},
"section" : [
{
"title" : "Genetics and Pharmacogenomics",
"code" : {
"text" : "section8.6.1-genetics-pharmacogenomics"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include any specific instructions for the collection and assay of samples for genetic and/or pharmacogenomic analysis. If genetic testing is not included in the study, state “Not Applicable.” • Describe the biological samples that will be collected (for example, tissue, serum, plasma, etc.), handling of samples, and the assay method. o Specific sample collection and processing instructions can be described in an appendix or a separate document and cross-referenced. • Describe the retention time for the samples (ensuring alignment with the ICF). • Indicate the types of analyses that may be studied for each sample.]</div>"
}
},
{
"title" : "Pharmacodynamic Biomarkers",
"code" : {
"text" : "section8.6.2-pharmacodynamics"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include any specific instructions for the collection of samples and assessment of pharmacodynamic biomarkers. If pharmacodynamic biomarker testing is not included in the study, state “Not Applicable.” • Describe the biological samples that will be collected (for example, tissue, serum, plasma, etc.). o Specific sample collection and processing instructions can be described in an appendix or a separate document and cross-referenced. • Describe the retention time for the samples (ensuring alignment with the ICF). • Indicate the types of biomarkers that will be studied for each sample. • Specify whether each sample is optional or required. Required samples must be based on a protocol objective.]</div>"
}
},
{
"title" : "Other Biomarkers",
"code" : {
"text" : "section8.6.3-other-biomarkers"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include any specific instructions for the collection of samples and assessment of other biomarkers. • Describe the biological samples that will be collected (for example, tissue, serum, plasma, etc.). o Specific sample collection and processing instructions can be described in an appendix or a separate document and cross-referenced. • Describe the retention time for the samples (ensuring alignment with the ICF). • Indicate the types of biomarkers that will be studied for each sample. • Specify whether each sample is optional or required. Required samples must be based on a protocol objective.]</div>"
}
}
]
},
{
"title" : "Immunogenicity Assessments",
"code" : {
"text" : "section8.7-immunogenicity-assessments"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include any specific instructions for the collection of samples and interpretation of immunogenicity. If immunogenicity assessments are included within Efficacy Assessments or Safety Assessments, cross-reference to that section. If immunogenicity testing is not included in the study, state “Not Applicable.”]</div>"
}
},
{
"title" : "Medical Resource Utilisation and Health Economics",
"code" : {
"text" : "section8.8-economics"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[This section does not apply to COAs. Include this section only for any value evidence and outcomes assessments not included in either the efficacy or safety sections. If medical resource utilization and health economics assessment is not included in the study, state “Not Applicable.” Describe the health outcome measures, collection method (for example, diary, physician interview), and participant burden.]</div>"
}
}
]
},
{
"title" : "Adverse Events, Serious Adverse Events, Product Complaints, Pregnancy and Postpartum Information",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section9-adverse-events"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Definitions",
"code" : {
"text" : "section9.1-definitions"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Definitions of Adverse Events",
"code" : {
"text" : "section9.1.1-definitions-adverse-events"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the AE definitions, including: •\tAny relevant regional AE requirements. •\tAny events that meet and do not meet the AE definition. •\tAny trial-specific AE clarifications. •\tThe trial-specific definition for an overdose. • If applicable, any clarifications on the AE and SAE definitions for efficacy trials (for example, lack of efficacy or failure of pharmacological actions reporting).]</div>"
}
},
{
"title" : "Definitions of Serious Adverse Events",
"code" : {
"text" : "section9.1.2-definitions-serious-adverse-events"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the SAE definitions, including: • Any relevant regional SAE requirements. •\tAny events that meet and do not meet the SAE definition. • Any trial-specific SAE clarifications.]</div>"
}
},
{
"title" : "Definitions of Medical Device Product Complaints",
"code" : {
"text" : "section9.1.3-definitions-product-complaints"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter Definition of Medical Device Product Complaints.]</div>"
}
}
]
},
{
"title" : "Timing and Mechanism for Collection and Reporting",
"code" : {
"text" : "section9.2-collection-methods"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the starting and ending time periods for and frequency of collecting AEs and SAEs. Cross refer to the Schedule of Assessments as appropriate.]</div>"
}
},
{
"title" : "Recording and Follow-Up",
"code" : {
"text" : "section9.3-recording-and-follow-up"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the Investigator’s actions for recording AEs and SAEs, including severity, causality, and the final outcome.]</div>"
},
"section" : [
{
"title" : "Identification",
"code" : {
"text" : "section9.3.1-identifying-events"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify how AEs, SAEs, product complaints and pregnancy and postpartum information will be identified (for example, spontaneous reporting, solicited questions).]</div>"
}
},
{
"title" : "Severity",
"code" : {
"text" : "section9.3.2-severity"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the intensity rating categories/scale.]</div>"
}
},
{
"title" : "Causality",
"code" : {
"text" : "section9.3.3-causality"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the causality categories/scale and the procedures for assessing causality.]</div>"
}
},
{
"title" : "Follow-up",
"code" : {
"text" : "section9.3.4-followup"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the procedures for follow-up of AEs, SAEs, pregnancy and product complaints. Include the assessment tools that will be used to monitor the events and the duration of follow-up after appearance of the events. Specify any procedures to be used for trials in which death is not an endpoint.]</div>"
}
}
]
},
{
"title" : "Reporting",
"code" : {
"text" : "section9.4-reporting-events"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the SAE reporting method (for example, an electronic data collection tool or a paper CRF) and reporting timeline to the Sponsor.]</div>"
},
"section" : [
{
"title" : "Regulatory Reporting Requirements",
"code" : {
"text" : "section9.4.1-regulatory-requirements"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify: •\tThe investigators’ responsibilities for reporting SAEs and Medical Device Product Complaints to the Sponsor (and to Ethics Committees, where required), specifying timing of reporting to allow the Sponsor to meet their responsibilities •\tThe Sponsor’s legal/regulatory responsibilities to report SAEs to regulatory authorities, ethics committees, and investigators •\tSerious and unexpected adverse reaction reporting]</div>"
}
},
{
"title" : "Adverse Events of Special Interest",
"code" : {
"text" : "section9.4.2-special-interest"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify any Adverse Events of Special Interest (AESI): •\tOther events that merit reporting to the Sponsor, trial leadership, IRB, and regulatory agencies (for example, secondary malignancies in oncology trials). •\tOther reportable events not already included in the previous sections, such as cardiovascular events, medical device incidents (including malfunctions), laboratory test abnormalities, and trial intervention overdose. Include the following for each AESI: •\tThe definition of the event. Specify the MedDRA preferred terms to use to report the AESI. •\tIf it is a measurable quantity, specify how will the measurement be done. •\tIf it is a clinical event, specify how will it be confirmed.]</div>"
}
},
{
"title" : "Disease-related Events or Outcomes Not Qualifying as AEs or SAEs",
"code" : {
"text" : "section9.4.3-disease-related-events"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify any Disease-Related Events (DREs), disease-related outcomes (DROs), or both that will not be reported as AEs or SAEs (for example, seizures in anticonvulsant trials) or state not applicable.]</div>"
}
}
]
},
{
"title" : "Pregnancy and Postpartum Information",
"code" : {
"text" : "section9.5-pregnancy-postpartum"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Participants Who Become Pregnant During the Trial",
"code" : {
"text" : "section9.5.1-pregnant"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify • the assessments to be performed, •\ttype and duration of monitoring, • whether participants who become pregnant during the trial must be discontinued from trial intervention (refer to Section 7 as applicable), and •\twhat information will be collected about a participant who becomes pregnant during the trial (for example, recording and reporting to the Sponsor, postpartum follow-up, trial intervention discontinuation or continuation, or trial withdrawal). For postpartum follow-up, include the time period (for example, initial child development) with the justification. If exposure to trial intervention during breastfeeding is applicable, specify •\tthe assessments to be performed, • type and duration of monitoring, and •\twhat information will be collected for both the participant and child. While pregnancy itself is not considered to be an AE or SAE, if negative or consequential outcome occurs in the participant or child/foetus, it will be reported as an AE or SAE. Refer to Section 9 for AE and SAE related procedures as applicable. If the negative event meets the seriousness criteria, then this is considered an SAE (for example, spontaneous abortion, foetal death, stillbirth, congenital anomalies, ectopic pregnancy, or pre-eclampsia) and reported per Section 9.4.]</div>"
}
},
{
"title" : "Participants Whose Partners Become Pregnant",
"code" : {
"text" : "section9.5.2-pregnant-partner"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify: • If the investigator will attempt to collect pregnancy information about a participant’s partner, who becomes pregnant during the specified period in the trial, • Whether the participant whose partner becomes pregnant should be discontinued from trial intervention (refer to Section 7 as applicable), and •\tThe assessments to be performed, type and duration of monitoring, and what information will be collected.]</div>"
}
}
]
}
]
},
{
"title" : "Statistical Considerations",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section10-statistics"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Ensure that the data analysis complies with ICH E9 Guideline and ICH E9(R1) Guideline. In general, all relevant data collected in the trial should be considered in this section. No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "General Considerations",
"code" : {
"text" : "section10.1-general-considerations"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Provide statements relevant to statistical considerations in general. For example, this might include statements indicating whether there is a separate statistical analysis plan, which general summary statistics will be provided, and when the analyses will be conducted (e.g., “The analysis will be conducted on all participant data at the time the trial ends.”).]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Analysis Sets",
"code" : {
"text" : "section10.2-analysis-sets"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe analysis sets to be considered at the trial level, i.e., the set of participants whose data are to be included in the analyses.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Analyses of Demographics and Other Baseline Variables",
"code" : {
"text" : "section10.3-analyses-demographics"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the summary statistics that will be used to describe the distribution of demographic and other relevant variables at baseline. Specify the timing of the measurement of the variables (e.g., at inclusion in the trial; before , or at randomization). Relevant variables include, but are not limited to: stratification variables specified in Section 6.8, covariates for the statistical models specified in Section 10.4, other suspected predictive or prognostic variables, and variables used for planned subgroup analyses.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Analyses Associated with the Primary Objective(s)",
"code" : {
"text" : "section10.4-analysis-primary-objective"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No content here. Create a new section for each estimand.]</div>"
},
"section" : [
{
"title" : "Analysis Associated with a Primary Objective",
"code" : {
"text" : "section10.4-analysis-primary-objective-instance"
},
"focus" : {
"type" : "EvidenceVariable",
"display" : "[Replace with VariableDefinition Profile of EvidenceVariable Resource.]"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Statistical Method of Analysis",
"code" : {
"text" : "section10.4.1-statistical-method"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the statistical analysis methods that will be used to evaluate the primary objective(s) and associated estimand(s) in Section 3.1. Ensure that the statistical hypothesis/model/analysis (and corresponding assumptions) is aligned with the primary estimand(s). For each objective, state the null and alternative hypotheses, including the pre-planned type 1 error rate, or alternative criteria for evaluating whether the objective has been met, and relevant operating characteristics if appropriate. Describe the statistical model used and the factors that will be included (covariates and interactions) and any rules for handling these factors (for example, pooling of centres). If modelling and simulation methods are to be used, please describe the model (inputs and outputs), the underlying assumptions, and the method of model fitting. Entries should Reference EndpointAnalysisPlan Profile of Evidence Resource.]</div>"
}
},
{
"title" : "Handling of Data in Relation to Primary Estimand(s)",
"code" : {
"text" : "section10.4.2-data-handling"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[For each intercurrent event of the primary estimand(s) (Section 3.1, Estimand[s] for the Primary Objective[s]), explain how data will be handled for the statistical analysis in line with the primary estimand. The handling of intercurrent events in statistical analysis should be aligned with the specific estimand strategies being used. This section should describe with more detail the rationale and handling of the data rather than repeating the guidance from the preceding sections.]</div>"
}
},
{
"title" : "Handling of Missing Data",
"code" : {
"text" : "section10.4.3-missing-data-handling"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe how missing data will be addressed (e.g., imputation method and model), state the underlying assumptions, and provide a rationale for the approach. Refer to the E9(R1) addendum when the estimand framework is used.]</div>"
}
},
{
"title" : "Sensitivity Analysis",
"code" : {
"text" : "section10.4.4-sensitivity-analysis"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe sensitivity analyses. Sensitivity analyses are a series of analyses conducted with the intent to explore the robustness of inferences from the main estimator to deviations from its underlying modelling assumptions and limitations in the data. Entries should Reference EndpointAnalysisPlan Profile of Evidence Resource.]</div>"
}
},
{
"title" : "Supplementary Analysis",
"code" : {
"text" : "section10.4.5-supplementary-analysis"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe any supplementary analysis if applicable. Supplementary analyses are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.]</div>"
}
}
]
}
]
},
{
"title" : "Analyses Associated with the Secondary Objective(s)",
"code" : {
"text" : "section10.5-analysis-secondary-objective"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No content here. Create a new section for each estimand.]</div>"
},
"section" : [
{
"title" : "Analysis Associated with a Secondary Objective",
"code" : {
"text" : "section10.5-analysis-secondary-objective-instance"
},
"focus" : {
"type" : "EvidenceVariable",
"display" : "[Replace with VariableDefinition Profile of EvidenceVariable Resource.]"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Statistical Method of Analysis",
"code" : {
"text" : "section10.5.1-statistical-method"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Clearly specify any secondary hypotheses that will be tested for confirmatory purposes. Entries should Reference EndpointAnalysisPlan Profile of Evidence Resource.]</div>"
}
},
{
"title" : "Handling of Data in Relation to Secondary Estimand(s)",
"code" : {
"text" : "section10.5.2-data-handling"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter Handling of Data in Relation to Secondary Estimand(s)]</div>"
}
},
{
"title" : "Handling of Missing Data",
"code" : {
"text" : "section10.5.3-missing-data-handling"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe how missing data will be addressed (e.g., imputation method and model), state the underlying assumptions, and provide a rationale for the approach. Refer to the E9(R1) addendum when the estimand framework is used.]</div>"
}
},
{
"title" : "Sensitivity Analysis",
"code" : {
"text" : "section10.5.4-sensitivity-analysis"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe sensitivity analyses. Sensitivity analyses are a series of analyses conducted with the intent to explore the robustness of inferences from the main estimator to deviations from its underlying modelling assumptions and limitations in the data. Entries should Reference EndpointAnalysisPlan Profile of Evidence Resource.]</div>"
}
},
{
"title" : "Supplementary Analysis",
"code" : {
"text" : "section10.5.5-supplementary-analysis"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe any supplementary analysis if applicable. Supplementary analyses are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.]</div>"
}
}
]
}
]
},
{
"title" : "Analyses Associated with the Exploratory Objective(s)",
"code" : {
"text" : "section10.6-analysis-exploratory-objective"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe any exploratory analyses, if applicable. Additional subsections could be created to describe the analyses, as needed.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Safety Analyses",
"code" : {
"text" : "section10.7-safety-analyses"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If safety is a primary and/or secondary objective, describe the corresponding safety analyses in the appropriate section above (Section 10.2 or Section 10.3).]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Other Analyses",
"code" : {
"text" : "section10.8-other-analyses"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe Other Analyses such as Subgroup analyses, Adjusted analysis if needed.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Interim Analyses",
"code" : {
"text" : "section10.9-interim-analyses"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe any interim analysis and criteria for stopping or adapting the trial. The description should include, but is not limited to, the following: •\tAny interim analysis plan, even if it is only to be performed at the request of an oversight body (for example, DMC). •\tDescribe (briefly and concisely) and reference the applied statistical method, for example, group sequential test and spending function (for example, O’Brien-Fleming), as applicable. •\tWho will perform the analyses. •\tWhen they will be conducted (timing and/or triggers). •\tThe decision criteria—statistical or other—that will be adopted to judge the interim results as part of a guideline for early stopping or other adaptations. •\tWho will see the outcome data while the trial is ongoing. •\tWhether these individuals will remain blinded to trial groups. •\tHow the integrity of the trial implementation will be protected (for example, maintaining blinding) when any adaptations to the trial are made. •\tWho has the ultimate authority to stop or modify the trial, for example, investigator, principal investigator, Data Monitoring Committee, or sponsor. •\tThe stopping guidelines. •\tIf pre-specified interim analyses are to be used for other trial adaptations such as sample size re-estimation, alteration to the proportion of participants allocated to each trial group, and changes to eligibility criteria.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Multiplicity Adjustments",
"code" : {
"text" : "section10.10-multiplicity-adjustments"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Multiple testing procedures may be needed to limit the probability of false positive findings in a trial. Reasons for carrying out multiple statistical tests include - but are not restricted to - multiple endpoints, multiple treatment groups, multiple hypotheses, subgroups, different statistical methods, etc. Describe any approaches to multiplicity control for the trial. This description might go beyond the analysis of primary objectives. Specify the statistical approach to control the overall type I error rate as well as the (adjusted) significance levels to test specific hypotheses, as applicable. Clarify whether the tests/confidence intervals are one- or two-sided. State the circumstances under which a study will be considered to have met its primary objective(s). For example, in a study with two primary efficacy endpoints, this section should state whether the study would be expected to provide evidence on at least one or on both of the endpoints in order to confirm the efficacy of the treatment. For some statistical approaches it might be helpful to include a graphical depiction, as visualization will be helpful for understanding, coupled with the clinical translation of the mathematical choices. Details regarding Interim Analyses should be provided in section 10.9.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Sample Size Determination",
"code" : {
"text" : "section10.11-sample-size-determination"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[This section should detail the methods used for the determination of the sample size and a reference to tables or statistical software used to carry out the calculation. Sufficient information should be provided so that the sample size calculation can be reproduced or described. If the planned sample size is not derived statistically, then this should be explicitly stated along with a rationale for the intended sample size (for example, exploratory nature of pilot trials; pragmatic considerations for trials in rare diseases). Entries should Reference EndpointAnalysisPlan Profile of Evidence Resource.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
}
]
},
{
"title" : "Trial Oversight and Other General Considerations",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section11-oversight"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Regulatory and Ethical Considerations",
"code" : {
"text" : "section11.1-regulatory-considerations"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Concisely summarize the prevailing ethical, legal, and regulatory guidelines that will be applied throughout the trial. For example, This trial will be conducted in accordance with the protocol and with the following: • Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and the Council for International Organisations of Medical Sciences (CIOMS) International Ethical Guidelines • ICH Good Clinical Practice (GCP) Guidelines • Applicable laws and regulations]</div>"
}
},
{
"title" : "Trial Oversight",
"code" : {
"text" : "section11.2-trial-oversight"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Concisely summarize the trial oversight listing the investigator and sponsor responsibilities not covered in other sections of the protocol which are essential for the operations of the trial, specifying the ones related to quality assurance.]</div>"
},
"section" : [
{
"title" : "Investigator Responsibilities",
"code" : {
"text" : "section11.2.1-investigator-responsibilities"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter Investigator Responsibilities.]</div>"
}
},
{
"title" : "Sponsor Responsibilities",
"code" : {
"text" : "section11.2.2-sponsor-responsibilities"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the sponsor duties to be delegated to a third party that may impact the investigators sites, if applicable.]</div>"
}
}
]
},
{
"title" : "Informed Consent Process",
"code" : {
"text" : "section11.3-informed-consent-process"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify the key elements of the informed consent process, including any special needs and how these are addressed (for example, assent, capacity, legally acceptable representative, adolescents who may reach age of majority during the trial, pregnant participants and pregnant partners of participants).]</div>"
},
"section" : [
{
"title" : "Assent Process",
"code" : {
"text" : "section11.3.0-assent-process"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter Description of Assent Process.]</div>"
}
},
{
"title" : "Emergency Consent Process",
"code" : {
"text" : "section11.3.0-emergency-consent-process"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If enrollment in the trial may occur during an emergency in which the participant or their legally acceptable representative is not able or available to give consent, describe the consent process.]</div>"
}
},
{
"title" : "Informed Consent for Rescreening",
"code" : {
"text" : "section11.3.1-rescreening-consent-process"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If participants can be rescreened, add the text to state whether the participant needs to complete a new consent. Screen failure and rescreening should be clearly defined in the protocol, with cross-reference to those definitions.]</div>"
}
},
{
"title" : "Informed Consent for Remaining Samples in Exploratory Research",
"code" : {
"text" : "section11.3.2-remaining-samples"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If any exploratory research is planned and additional written consent regarding the use of remaining samples for exploratory research will be obtained, describe the consent process.]</div>"
}
}
]
},
{
"title" : "Committees",
"code" : {
"text" : "section11.4-committees"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Briefly describe the administrative structure of committees that will be reviewing data while the trial is ongoing, and the type of committee (for example, Dose Escalation Committee, Data Monitoring Committee or Data Safety Monitoring Board). Note that specific details may be required depending on local law or regulation. If applicable, Committee Charters may be cross-referenced. If no committees are applicable, state “Not Applicable.”]</div>"
}
},
{
"title" : "Insurance and Indemnity",
"code" : {
"text" : "section11.5-insurance-and-indemnity"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Concisely summarize the arrangements for participants insurance and indemnity if not addressed in a separate agreement, if required by the applicable regulatory requirements.]</div>"
}
},
{
"title" : "Risk Management",
"code" : {
"text" : "section11.6-risk-management"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe how the critical to quality factors will be mitigated. It is important to determine the risks that threaten their integrity and decide whether they can be accepted or should be mitigated, based on their probability, detectability and impact. Where it is decided that risks should be mitigated, the necessary control processes should be put in place and communicated, and the necessary actions taken to mitigate the risks.]</div>"
}
},
{
"title" : "Data Governance",
"code" : {
"text" : "section11.7-data-governance"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the key processes for critical trial integrity, traceability and security enabling accurate collection, reporting, monitoring, transfer, retention, access and publication if not addressed in separate agreement(s). Describe the measures to protect the privacy and confidentiality of personal information of trial participants in accordance with applicable regulatory requirements on personal data protection and any measures that should be taken in case of a data security breach.]</div>"
}
},
{
"title" : "Source Data",
"code" : {
"text" : "section11.8-source-data"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Establish the importance of source data and expectation for traceability of transcribed information back to source. Delineate expectations for investigators (for example, maintain source data at the site, ensure availability of current records) and trial monitors (for example, verify CRF data relative to source, safety of participants is being protected, conduct is in accordance with GCP). Define what constitutes source data and its origin or provide a reference to the location of these definitions, if contained in a separate document, such as a monitoring guideline or source data acknowledgement). Describe the provision for direct access to source data and documents enabling clinical trial-related monitoring, audits and regulatory inspections, if not included in separate agreement(s).]</div>"
}
},
{
"title" : "Protocol Deviations",
"code" : {
"text" : "section11.9-protocol-deviations"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Plans for detecting, reviewing, and reporting any deviations from the protocol should be described or a reference to separate document included.]</div>"
}
},
{
"title" : "Early Site Closure",
"code" : {
"text" : "section11.10-early-site-closure"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Decision Rights for Site Closure",
"code" : {
"text" : "section11.10-early-site-closure#decisionRights"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[List the sponsor’s rights to close a site. Likewise, list the investigator’s rights to initiate early site closure.]</div>"
}
},
{
"title" : "Crteria for Early Closure",
"code" : {
"text" : "section11.10-early-site-closure#criteria"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[List the criteria for early closure of a site by the sponsor or investigator.]</div>"
}
},
{
"title" : "Responsibilities Following Early Site Closure",
"code" : {
"text" : "section11.10-early-site-closure#responsibilities"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[List the responsibilities of the sponsor and investigator following early site closure, such as informing the ethics committee(s), and prompt notification of the participant and transition to appropriate therapy and/or follow-up.]</div>"
}
}
]
}
]
},
{
"title" : "Appendix: Supporting Details",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section12-supporting-details"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Clinical Laboratory Tests",
"code" : {
"text" : "section12.1-clinical-laboratory-tests"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Specify which laboratory parameters should be included in each clinical laboratory assessment panel (for example, for haematology, chemistry, urinalysis). A tabular presentation for such information is common. If applicable, include equations and references for locally calculated laboratory results. If not applicable, retain header and enter “Not Applicable.”]</div>"
}
},
{
"title" : "Country/Region-Specific Differences",
"code" : {
"text" : "section12.2-country-specific-differences"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Although global clinical trial practices are increasingly harmonised, some country/ region-specific differences in requirements do exist (for example, document retention periods, contraception requirements). Where differences in requirements cannot be reconciled, sponsors should explain how they will document and communicate country/region-specific differences (for example, by country/region-specific amendments or addenda). An alternative to country/region-specific amendments is to list the specific differences by country or countries in this section, including a reference to the relevant section of the protocol where the differing requirement applies. If not applicable, retain header and enter “Not Applicable.”]</div>"
}
},
{
"title" : "Prior Protocol Amendment(s)",
"code" : {
"text" : "section12.3-prior-protocol-amendments"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[See M11 for specific guidance if not able to simply state {Not applicable. This protocol has not been amended.} or {Not applicable. This is the first protocol amendment.}.]</div>"
}
}
]
},
{
"title" : "Appendix: Glossary of Terms and Abbreviations",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section13-glossary"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Define abbreviations and other terms used in the protocol. A tabular presentation is common and may serve as the definition at first use. Entries should Reference ValueSet Resource or CodeSystem Resource.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Appendix: References",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section14-references"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[References should be listed in a common format that includes all relevant information to identify the source and date published. If not published, this should be clearly indicated. Entries should Reference Citation Resource.]</div>"
}
},
{
"title" : "Title Page",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "defined-in-text",
"display" : "Defined in text"
}
],
"text" : "section0-title-page"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (header only).]</div>"
},
"section" : [
{
"title" : "Sponsor Confidentiality Statement",
"code" : {
"text" : "section0.1-sponsor-confidentiality-statement"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Insert the Sponsor’s confidentiality statement, if applicable, otherwise delete.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Full Title",
"code" : {
"text" : "section0.2-full-title"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Instructions are: [The protocol should have a descriptive title that identifies the scientific aspects of the trial sufficiently to ensure it is immediately evident what the trial is investigating and on whom, and to allow retrieval from literature or internet searches.]</div>"
}
},
{
"title" : "Trial Acronym",
"code" : {
"text" : "section0.3-trial-acronym"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Acronym or abbreviation used publicly to identify the clinical trial, if any. Delete this line from the table if not applicable.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Sponsor Protocol Identifier",
"code" : {
"text" : "section0.4-protocol-identifier"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[A unique alphanumeric identifier for the trial, designated by the Sponsor, is a standard part of trial data, and should be included for most trials.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Original Protocol",
"code" : {
"text" : "section0.5-original-protocol"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter 'Yes' or 'No'.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Version Number",
"code" : {
"text" : "section0.6-version-number"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[An optional field for use by the Sponsor at their discretion.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Version Date",
"code" : {
"text" : "section0.7-version-date"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[An optional field for use by the Sponsor at their discretion.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Amendment Identifier",
"code" : {
"text" : "section0.8-amendment-identifier"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter the amendment identifier (e.g., amendment number). If this is the original instance of the protocol, leave blank.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Amendment Scope",
"code" : {
"text" : "section0.9-amendment-scope"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Leave blank for original protocol. If an amendment applies to all sites in the trial, enter “global” and delete the Country, Region and Site Identifier fields. If amending a single-country study, enter “global”. If the amendment does not apply to all sites in the trial, select “Not Global” and utilize one of the identifiers based on amendment scope. Use the ISO-3166 region or country identifier (for example, DE or EU).]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Compound Code(s)",
"code" : {
"text" : "section0.10-compound-code"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter the Sponsor’s unique identifier for investigational compound(s) in the trial. Add fields as needed.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Compound Name(s)",
"code" : {
"text" : "section0.11-compound-name"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Delete this line from the table if a nonproprietary name has not yet been assigned. Omit proprietary name fields if not yet established.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Trial Phase",
"code" : {
"text" : "section0.12-trial-phase"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[For trials combining investigational drugs or vaccines with devices, classify according to the phase of drug development.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Short Title",
"code" : {
"text" : "section0.13-short-title"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Short title should convey in plain language what the trial is about and is suitable for use as “Brief Title” or “Title in Plain Language” in global clinical trial registries. It can also be suitable for use with informed consents and ethics committee submissions.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Sponsor Name and Address",
"code" : {
"text" : "section0.14-sponsor-name-address"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[{Enter Sponsor Name} {Enter Sponsor Legal Address} {Enter Co-Sponsor Name} {Enter Co-Sponsor Legal Address} Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field. Local Sponsor Name and Address: {Enter Local Sponsor Name} {Enter Local Sponsor Address} In some countries, the clinical trial Sponsor may be the local affiliate company (or designee). In such cases, indicate in the Sponsor Local Name and Address Field.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Manufacturer Name and Address",
"code" : {
"text" : "section0.15-manufacturer"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Manufacturer name and address information is required only for protocols that include investigational device(s) and should not be included for other protocols. Include the manufacturer address only if the manufacturer is different than the Sponsor listed above. Add additional fields as needed if multiple investigational devices will be used in the trial. Delete this line from the table if not applicable.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Regulatory Agency Identifier Number(s)",
"code" : {
"text" : "section0.16-regulatory-identifiers"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[{EU CT Number, IDE Number, FDA IND Number, JRCT Number, NCT Number, NMPA IND Number, WHO/UTN Number, Other Regulatory Agency Identifier Number} Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for “other” if more than one is needed.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Sponsor Approval Date",
"code" : {
"text" : "section0.17-sponsor-approval-date"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter Approval Date or state location where information can be found. All versions should be uniquely identifiable. Use the CDISC date format (dd/mmm/yyyy, for example 07/JUN/2015) to indicate the date the protocol (or amendment) was approved by the Sponsor.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Sponsor Signatory",
"code" : {
"text" : "section0.18-sponsor-signatory"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Include either the sponsor signature (name and title of sponsor signatory and signature date) or the statement {This protocol was approved via [describe method] as described on the approval page appended to the document.}.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Medical Expert Contact",
"code" : {
"text" : "section0.19-medical-expert-contact"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Enter contact information for Medical Expert (as designated by sponsor) or state location where information can be found.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "SAE Reporting Method",
"code" : {
"text" : "section0.20-sae-reporting-method"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Report Serious Adverse Events to the sponsor [Enter SAE reporting method(s)] Refer to Section 9.4 for detailed reporting instructions.]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
},
{
"title" : "Amendment Details",
"code" : {
"text" : "section0.21-amendment-details"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[State {Not applicable. This protocol has not been amended.} or state {This protocol has been amended previously. Details of prior amendments are presented in Prior Protocol Amendment(s).} or include Current Amendment details as appropriate (See instructions).]</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "notstarted",
"display" : "Not Started"
}
]
}
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change